cerecor
appoints
gilla
kaplan
board
directors
rockville
md
chesterbrook
globe
newswire
cerecor
nasdaq
cerc
biopharmaceutical
company
focused
becoming
leader
development
commercialization
treatments
rare
orphan
diseases
today
announced
appointment
gilla
kaplan
board
directors
kaplan
brings
years
academic
industry
experience
pleased
welcome
kaplan
board
said
sol
barer
chairman
board
dr
kaplan
brings
decades
academic
industry
experience
making
natural
fit
cerecor
advance
pipeline
targeting
rare
diseases
disorders
look
forward
board
exciting
time
kaplan
recognized
authority
various
aspects
host
immune
response
mycobacterial
pathogens
including
causative
agents
leprosy
tuberculosis
tb
director
global
health
program
tuberculosis
bill
melinda
gates
foundation
bmgf
january
april
work
encompassed
developing
deep
understanding
cellular
immune
response
harness
host
adjunctive
therapies
spent
career
academic
research
scientist
leading
laboratory
investigations
focusing
human
disease
exploring
novel
experimental
medicine
approaches
modulate
immune
response
disease
control
building
research
experience
rockefeller
university
new
york
city
years
public
health
research
institute
center
umdnj
years
led
reshaping
tuberculosis
program
bmgf
kaplan
recipient
multiple
grants
funding
organizations
research
kaplan
served
board
directors
celgene
currently
member
tyra
bioscience
board
directors
excited
work
cerecor
said
kaplan
pipeline
focused
rare
diseases
disorders
especially
exciting
background
immunology
immune
modulation
cerecor
made
great
progress
pipeline
date
happy
join
time
company
making
great
strides
advancing
programs
clinical
cerecor
cerecor
biopharmaceutical
company
focused
becoming
leader
development
commercialization
treatments
rare
orphan
diseases
company
advancing
pipeline
innovative
therapies
address
unmet
patient
needs
within
rare
orphan
diseases
company
rare
disease
pipeline
includes
compounds
therapies
inherited
metabolic
disorders
known
congenital
disorders
glycosylation
food
drug
administration
fda
granted
rare
pediatric
disease
designation
rpdd
orphan
drug
designation
odd
three
compounds
thus
potentially
qualifying
company
receive
priority
review
voucher
prv
upon
approval
new
drug
application
nda
company
also
developing
monoclonal
antibody
developed
treatment
acute
respiratory
distress
syndrome
severe
crohn
disease
dual
mtor
inhibitor
developed
treatment
complex
lymphatic
malformations
granted
odd
rpdd
fda
thus
potentially
qualifying
company
receive
fourth
prv
upon
approval
nda
monoclonal
antibody
developed
treatment
autoimmune
inflammatory
diseases
adult
onset
stills
disease
multiple
myeloma
information
cerecor
please
visit
statements
press
release
may
include
statements
made
pursuant
private
securities
litigation
reform
act
statements
statements
historical
facts
statements
subject
significant
risks
uncertainties
subject
change
based
various
factors
many
beyond
cerecor
control
could
cause
actual
results
differ
statements
statements
may
include
without
limitation
statements
respect
cerecor
plans
objectives
projections
expectations
intentions
statements
identified
words
projects
may
could
would
continue
seeks
aims
predicts
believes
expects
anticipates
estimates
intends
plans
potential
similar
expressions
including
use
negative
discussions
future
matters
development
product
candidates
products
timing
success
trial
results
regulatory
review
potential
attributes
benefits
product
candidates
statements
historical
statements
based
upon
current
beliefs
expectations
cerecor
management
subject
significant
risks
uncertainties
including
drug
development
costs
timing
risks
including
reliance
investigators
enrollment
patients
clinical
trials
regulatory
risks
impacts
pandemic
clinical
trials
company
economy
general
cerecor
cash
position
need
raise
additional
capital
risks
detailed
cerecor
filings
securities
exchange
commission
actual
results
may
differ
set
forth
statements
except
required
applicable
law
cerecor
expressly
disclaims
obligations
undertaking
release
publicly
updates
revisions
statements
contained
herein
reflect
change
cerecor
expectations
respect
thereto
change
events
conditions
circumstances
statement
based
media
investor
inquiries
james
harrell
investor
relations
chief
commercial
officer
cerecor
jharrell
office
